Your browser doesn't support javascript.
loading
Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions.
Jönsson, Peter; Southcombe, Jennifer H; Santos, Ana Mafalda; Huo, Jiandong; Fernandes, Ricardo A; McColl, James; Lever, Melissa; Evans, Edward J; Hudson, Alexander; Chang, Veronica T; Hanke, Tomás; Godkin, Andrew; Dunne, Paul D; Horrocks, Mathew H; Palayret, Matthieu; Screaton, Gavin R; Petersen, Jan; Rossjohn, Jamie; Fugger, Lars; Dushek, Omer; Xu, Xiao-Ning; Davis, Simon J; Klenerman, David.
Afiliación
  • Jönsson P; Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom; Department of Chemistry, Lund University, SE-22100 Lund, Sweden;
  • Southcombe JH; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom; Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford OX3 9DU, United Kingdom;
  • Santos AM; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Huo J; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Fernandes RA; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • McColl J; Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom;
  • Lever M; Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom;
  • Evans EJ; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Hudson A; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Chang VT; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Hanke T; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Godkin A; Department of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom;
  • Dunne PD; Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom;
  • Horrocks MH; Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom;
  • Palayret M; Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom;
  • Screaton GR; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom;
  • Petersen J; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia;
  • Rossjohn J; Department of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; Australian Research C
  • Fugger L; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom; Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford OX3 9DS, Unit
  • Dushek O; Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom;
  • Xu XN; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; x.xu@imperial.ac.uk simon.davis@imm.ox.ac.uk dk10012@cam.ac.uk.
  • Davis SJ; MRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, United Kingdom; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom; x.xu@imperial.ac.uk simon.davis@imm.ox.ac.uk dk10012@cam.ac.uk.
  • Klenerman D; Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom; x.xu@imperial.ac.uk simon.davis@imm.ox.ac.uk dk10012@cam.ac.uk.
Proc Natl Acad Sci U S A ; 113(20): 5682-7, 2016 May 17.
Article en En | MEDLINE | ID: mdl-27114505
ABSTRACT
The αß T-cell coreceptor CD4 enhances immune responses more than 1 million-fold in some assays, and yet the affinity of CD4 for its ligand, peptide-major histocompatibility class II (pMHC II) on antigen-presenting cells, is so weak that it was previously unquantifiable. Here, we report that a soluble form of CD4 failed to bind detectably to pMHC II in surface plasmon resonance-based assays, establishing a new upper limit for the solution affinity at 2.5 mM. However, when presented multivalently on magnetic beads, soluble CD4 bound pMHC II-expressing B cells, confirming that it is active and allowing mapping of the native coreceptor binding site on pMHC II. Whereas binding was undetectable in solution, the affinity of the CD4/pMHC II interaction could be measured in 2D using CD4- and adhesion molecule-functionalized, supported lipid bilayers, yielding a 2D Kd of ∼5,000 molecules/µm(2) This value is two to three orders of magnitude higher than previously measured 2D Kd values for interacting leukocyte surface proteins. Calculations indicated, however, that CD4/pMHC II binding would increase rates of T-cell receptor (TCR) complex phosphorylation by threefold via the recruitment of Lck, with only a small, 2-20% increase in the effective affinity of the TCR for pMHC II. The affinity of CD4/pMHC II therefore seems to be set at a value that increases T-cell sensitivity by enhancing phosphorylation, without compromising ligand discrimination.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígenos CD4 / Antígeno HLA-A24 / Cadenas HLA-DRB1 Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2016 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígenos CD4 / Antígeno HLA-A24 / Cadenas HLA-DRB1 Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2016 Tipo del documento: Article